Cardiff Oncology vs Cervomed
Cervomed is the larger business, with $4.0m of revenue in fiscal 2025 against $593,000 for Cardiff Oncology (6.8 times as much). Cardiff Oncology grew faster (-13.2% against -58.9%). Cervomed kept more of each dollar of sales as profit: a net margin of -673.1% against -7732.0%.
| Latest fiscal year | Cardiff OncologyCRDF, 2025 | CervomedCRVO, 2025 |
|---|---|---|
| Revenue | $593,000 | $4.0m |
| Revenue growth | -13.2% | -58.9% |
| Net income | −$45.9m | −$27.0m |
| Operating margin | — | -706.2% |
| Net margin | -7732.0% | -673.1% |
| Return on equity | -71.5% | -93.9% |
| Free cash flow | −$38.0m | −$23.4m |
| Cash | $17.5m | $8.2m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 31 | 15 |
| Market value | $58.6m | $21.0m |
| Price vs our value range | — | — |
| Moat score | 5 (Weak) | — |
| Insider trades, 12 months | 4 buys, 0 sales | 19 buys, 0 sales |